5. data and comments. 5, page-145

re: 5. files important provisional patent in the u Files provisional patent in the United States

http://stocknessmonster.com/news-item?S=EPT&E=ASX&N=222750

Extract:
Michael Kleinig, EpiTan's Pharmaceutical and New Business Development Manager, said: "This patent application was filed to protect the use of Melanotan in all anticipated delivery formulations.

This means that no one else would be able to commercialise Melanotan, in a sustained release delivery formulation, irrespective of whether it is delivered by an implant, topically, orally (a pill), or other, for 20 years."

Dr Wayne Millen, EpiTan’s Executive Chairman and CEO, said: “The increased protection for EpiTan is significant. If this patent is granted it will be very difficult for any potential competitor to develop and bring to market, a commercially viable alternative.

An independent report has identified that the market for Melanotan is likely to be very lucrative. Accordingly we continue to enhance our intellectual property position.” EpiTan's intellectual property counsel confirmed that this patent application, if granted, would considerably strengthen EpiTan's IP portfolio.

The patent application has the potential for a further 20 years of market exclusivity for EpiTan, from the filing date, regarding the use of Melanotan to increase the levels of melanin in the skin via sustained release delivery methods.

EpiTan Limited abn 88 089 644 119
Level 10, 52 Collins Street Melbourne Victoria 3000 Australia Telephone +61 3 9662 4688 Facsimile +61 3 9662 4788 www.epitan.com.au